How ColoFIT changes bowel cancer referrals
NHS England has asked each Cancer Alliance to identify at least one local service ready to introduce a risk calculator such as ColoFIT. To help services make that change, the British Society of Gastroenterology and the Association of Coloproctology of Great Britain and Ireland have published a consensus statement endorsed by the IBMS and other professional bodies representing general practice, pathology and laboratory medicine.
At present, when a GP requests a faecal immunochemical test (FIT) for a patient with possible bowel cancer symptoms, the threshold for urgent referral is 10 micrograms of haemoglobin per gram of faeces. Two patients with the same FIT result therefore meet the same referral threshold, even if their ages and blood results suggest different levels of risk.
ColoFIT gives the GP a way to take those differences into account. It combines the actual FIT result with the patient’s age, sex and two measurements from a full blood count – mean corpuscular volume and platelet count – to estimate that patient’s risk of colorectal cancer.
Where a service adopts ColoFIT, the statement recommends urgent referral for patients over 18 whose estimated risk is 1% or higher. The practical difference is that a patient whose FIT result falls below 10 micrograms per gram could still meet the threshold for urgent investigation. Equally, a patient whose FIT result reaches 10 micrograms per gram could have an estimated risk below 1%. The GP discusses the result and next steps with the patient. An anal or rectal mass or ulceration still warrants immediate referral.
For laboratories, the first step is to check whether their FIT assay, FIT positivity rate and cancer detection rate match the conditions in which ColoFIT was developed. If they differ, the statement calls for local validation before the calculator is introduced. Laboratories that build ColoFIT into their laboratory information management system should also include it in their quality management processes and seek an extension to their UKAS scope of accreditation.
Read the full ColoFIT statement (PDF).